Cell and Gene Therapy Market Sales, Revenue and Growth Rate 2025-2030
The global cell and gene therapy market is undergoing rapid expansion, driven by the surge in regulatory approvals and continual advancements in therapeutic technologies. The market is anticipated to register a robust compound annual growth rate (CAGR) of approximately 23% during the forecast period. This strong growth trajectory is supported by escalating biopharmaceutical R&D investments, an encouraging regulatory landscape, and the widening clinical applications of gene-modified and cell-based treatment modalities.
Get Free Sample Report: https://meditechinsights.com/cell-and-gene-therapy-market/request-sample/
Cell and gene therapies are at the forefront of medical innovation, offering the potential to address diseases at their fundamental genetic and cellular levels. Cell therapy involves the introduction, modification, or replacement of living cells to restore normal function or repair damaged tissues, playing a critical role in regenerative medicine and immuno-oncology. Conversely, gene therapy focuses on altering or substituting defective genes to correct underlying genetic abnormalities responsible for various chronic and inherited disorders. Together, these modalities represent a paradigm shift in healthcare, opening new avenues for curing conditions once deemed incurable and attracting growing research and commercial attention.
Rising
Adoption of CAR-T Cell Therapy to Accelerate Market Growth
Chimeric Antigen Receptor T-cell (CAR-T) therapy is transforming cancer care,
particularly for hematologic malignancies, and stands as a major catalyst for
the cell and gene therapy market. The process reengineers a patient's T cells
to recognize and target specific cancer antigens, triggering highly effective immune
responses. The remarkable clinical success of CAR-T therapies in treating
relapsed or refractory leukemias and lymphomas has spurred global adoption and
regulatory approvals. Multiple CAR-T products are now commercially available,
and research continues to explore their potential against solid tumors and
autoimmune conditions. Furthermore, innovations in allogeneic or
"off-the-shelf" CAR-T therapies aim to simplify production, reduce costs, and
expand accessibility. As ongoing improvements enhance efficacy, scalability,
and safety, CAR-T therapies are expected to become a cornerstone of
personalized cancer treatment, propelling market expansion.
Emerging
Gene Editing Technologies Enhancing Accuracy and Reach
The advent of next-generation gene editing tools—such as CRISPR-Cas9, base
editing, and prime editing—is redefining the precision and possibilities of
gene therapy. These technologies allow scientists to target and repair
defective genes with exceptional accuracy and minimal side effects, significantly
improving therapeutic outcomes. Prime editing, in particular, provides greater
control over genetic modifications, unlocking new opportunities to treat rare
diseases and cancers. Artificial intelligence (AI) is further accelerating
progress by optimizing gene-target selection and enhancing editing efficiency.
Meanwhile, non-viral delivery systems like lipid nanoparticles are making gene
therapies safer, more cost-effective, and easier to scale. Collectively, these
advancements are paving the way for broader clinical use, improved patient
access, and stronger regulatory confidence in gene-based interventions.
Competitive
Landscape
The global cell and gene therapy market is characterized by a blend of
established pharmaceutical giants and innovative biotech firms. Key players
include Sartorius AG, Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA,
Charles River Laboratories, Cell and Gene Therapy Catapult, Lonza, WuXi AppTec,
Takara Bio Inc., Bristol Myers Squibb, FUJIFILM Holdings Corporation, and F. Hoffmann-La
Roche Ltd. Industry participants are pursuing strategies such as strategic
alliances, product innovation, and geographic expansion to strengthen their
competitive edge. As the market continues to evolve, collaboration between drug
developers, technology providers, and research institutions will be essential
in translating scientific breakthroughs into accessible, life-changing
therapies for patients worldwide.
Global Cell and Gene Therapy Market Segmentation
Market Size & Forecast (2023-2030), By Therapy Type, USD Million
- Cell Therapy
- Gene Therapy
Market Size & Forecast (2023-2030), By Indication, USD Million
- Oncology
- Autoimmune Diseases
- Neurological Diseases
- Cardiovascular Diseases
- Others
Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals & Speciality Clinics
- Pharma & Biotech Companies
- Academic Research Institutes
- Others
Key Request a free sample copy or view report summary: https://meditechinsights.com/cell-and-gene-therapy-market/request-sample/
About Us:
At Medi-Tech Insights, we are a global healthcare consulting firm committed to delivering premium insights and strategic solutions to help our clients navigate the complex and evolving healthcare landscape. Our team combines deep industry expertise with data-driven market intelligence to provide actionable insights that enable smarter decisions and sustainable success. With a strong focus on innovation, quality, and impact, Medi-Tech Insights has become a trusted partner for leading healthcare investors and corporates across the globe.
